Uso racional de medicamentos: temas selecionados, 2012.

Referências
1. BENAZZI, F. Classifying mood disorders
by age-at-onset instead of polarity. Prog.
Neuropsychopharmacol Biol. Psychiatry, [S. l.],
v. 33, p. 86–93, 2009.
2. ROY-BYRNE, P. P. et al. Low socioeconomic
status and mental health care use among
respondents with anxiety and depression in the
NCS-R. Psychiatr. Serv., [S. l.], v. 60, p. 1190–
1197, 2009.
3. SEEDAT, S. et al. Cross-national associations
between gender and mental disorders in the
World Health Organization World Mental Health
Surveys. Arch Gen Psychiatry, [S. l.], v. 66, p.
785–795, 2009.
4. NOCK, M. K. et al. Cross-national analysis of
the associations among mental disorders and
suicidal behavior: findings from the WHO World
Mental Health Surveys. PLOS. Med., [S. l.], v. 6, p.
e1000123, 2009.
5. PAYNE, N. A.; PRUDIC, J. Electroconvulsive
therapy: part II: a biopsychosocial perspective. J.
Psychiatr. Pract., [S. l.], v. 15, p. 369–390, 2009.
6. BARBUI, C. et al. Depression in adults:
drug and physical treatments. In.: BMJ Clinical
Evidence 2010. Web publication date: 15 Jun
2007 (based on April 2006 search).
7. MEAD, G. E. et al. Exercise for depression.
Cochrane Database of Systematic Reviews. In:
The Cochrane Library, n. 10, 2010. Art. No.
CD004366.
8. BUTLER, R. et al. Depression in adults:
psychological treatments and care pathways. BMJ
Clinical Evidence 2009. Web publication date: 15
Aug 2007 (based on April 2006 search).
9. GARBER, J. et al. Prevention of Depression in
At-Risk Adolescents. A Randomized Controlled
Trial. JAMA, [S. l.], v. 301, n. 2215-2224, 2009.
10. CUIJPERS, P. et al. Psychological
treatment of depression in primary care: a
meta-analysis. Br. J. Gen. Pract., [S. l.], v. 59,
n. 559, p. e51–60, 2009.
11. SARRIS, J.; KAVANAGH, D. J. Kava and St.
John’s wort: current evidence for use in mood
and anxiety disorders. J. Altern. Complement.
Med., [S. l.], v. 15, p. 827–836, 2009.
Ministério da Saúde
88
12. LINDE, K.; BERNER, M. M.; KRISTON, L.
St John’s wort for major depression. Cochrane
Database of Systematic Reviews. In: The Cochrane
Library, n. 10, 2010. Art. No. CD000448.
13. RAHIMI, R.; NIKFAR, S.; ABDOLLAHI, M.
Efficacy and tolerability of hypericum perforatum
in major depressive disorder in comparison with
selective serotonin reuptake inhibitors: a metaanalysis.
Prog. Neuropsychopharmacol Biol.
Psychiatry, [S. l.], v. 33, n. 1, p. 118-127, 2009.
14. HOU, W. H. et al. Treatment effects of
massage therapy in depressed people: a metaanalysis.
J. Clin. Psychiatry, [S. l.], v. 71, n. 7, p.
894–901, 2010.
15. WANNMACHER, L. Antidepressivos e lítio. In:
FUCHS, F. D.; WANNMACHER, L. Farmacologia
clínica: fundamentos da terapêutica racional. 4.
ed. Rio de Janeiro: GEN/Guanabara Koogan,
2010. p. 741–757.
16. BRASIL. Ministério da Saúde. Secretaria
de Ciência, Tecnologia e Insumos Estratégicos.
Departamento de Assistência Farmacêutica e
Insumos Estratégicos. Relação Nacional de
Medicamentos Essenciais: Rename 2010. 7. ed.
Brasília: Ministério da Saúde. 2010. 250 p.
17. TOHEN, M. et al. Olanzapine/fluoxetine
combination in patients with treatment-resistant
depression: rapid onset of therapeutic response
and its predictive value for subsequent overall
response in a pooled analysis of 5 studies. J. Clin.
Psychiatry, [S. l.], v. 71, n. 4, p. 451–462, 2010.
18. ARROLL, B. et al. Antidepressants versus
placebo for depression in primary care. Cochrane
Database of Systematic Reviews. In: The Cochrane
Library, n. 10, 2010. Art. No. CD007954.
19. GUAIANA, G.; BARBUI, C.; HOTOPF, M.
Amitriptyline for depression. Cochrane Database
of Systematic Reviews. In: The Cochrane
Library, n. 10, 2010. Art. No. CD004186.
20. CIPRIANI, A. et al. Fluoxetine versus other
types of pharmacotherapy for depression.
Cochrane Database of Systematic Reviews. In: The
Cochrane Library, n. 10, 2010. Art. No. CD004185.
21. STONE, M. et al. Risk of suicidality in clinical
trials of antidepressants in adults: analysis of
proprietary data submitted to US Food and Drug
Administration. BMJ, [S. l.], v. 339, p. b2880, 2009.